The Centre for Structural Heart Disease at the Dilawri Cardiovascular Institute positions itself at the forefront of innovation and patient-centered treatment. Employing cutting-edge minimally invasive techniques, the Centre is leading the way on exciting new treatments aimed at helping to improve care and outcomes for patients, including early recovery following transcatheter aortic valve replacement (TAVR) and advanced interventions for tricuspid and mitral valve diseases. Guided by the principles of equitable access, the Centre ensures that these life-saving procedures are available to diverse populations, striving to eliminate barriers to care and deliver outstanding outcomes for all patients regardless of background or circumstance.
Centre for Structural Heart Disease
Centre for Structural Heart Disease
Providing cutting-edge care for all with structural heart disease
Dr. David A Wood
Dr. David Wood is the Director of the Centre for Structural Heart Disease, UBC Centre for Cardiovascular Innovation (CCI) and Cardiac Catheterization Laboratory at Vancouver General Hospital. He is a professor of medicine and the Head of Cardiology at Vancouver General Hospital and the University of British Columbia Hospital. His primary research interests include transcatheter management of structural and valvular heart disease, new device development, novel strategies for treating acute coronary syndrome, and advanced cardiac imaging.
After obtaining his undergraduate medical degree from the University of British Columbia, Dr. Wood pursued residencies in internal medicine and cardiology and was named Chief Resident during his time in both programs. He went on to obtain subspecialty training at the Lenox Hill Heart and Vascular Institute of New York.
To date, Dr. Wood has participated in over 50 live-cases and 20 first-in-human cases and co-authored over 200 publications. He was the co-principal investigator of the CIHR funded COMPLETE trial that was presented as Late Breaking Science at the ESC 2019 and TCT 2019, with simultaneous publication in the New England Journal of Medicine and the Journal of the American College of Cardiology. Dr. Wood has recently secured funding for COMPLETE TAVR, an international RCT aimed at determining the optimal strategy for managing concomitant coronary artery disease in patients with symptomatic aortic stenosis. He was recently the recipient of the Luminary Award at the C3 Global Summit.
Dr. Wood currently serves as the President of the Canadian Association of Interventional Cardiology.
Dr. Scott Lim
Dr. Scott Lim is a clinical professor of medicine and pediatrics at the University of British Columbia and has served as the Medical Director of the University of Virginia Advanced Cardiac Valve Centre. He has focused his career on the development of novel therapies for valvular, structural and congenital heart disease and heart failure. His commitment to advancing care in these areas has led to his role as primary investigator in several transcatheter aortic, mitral, and pulmonary valve trials, as well as his involvement in the development and evaluation of many early-stage novel cardiac device therapies, particularly in mitral and tricuspid valve disease.
Dr. Lim completed his undergraduate medical training at the Mayo Medical School. He went on to complete a residency in pediatrics at the Wright State University School of Medicine and additional fellowship training in pediatric cardiology at the University of Michigan.
In addition to authoring more than 250 scientific publications, 500 presentations, and 50 book chapters, Dr. Lim has been the founding editor through five editions of the most popular textbook on congenital heart disease, the Field Guide to Congenital Heart Disease & Repair. He also has spent more than two decades leading a charitable organization focused on teaching cardiac disease care to physicians in developing countries.
